The EMA's CHMP committee recommendation is for Alofisel (darvadstrocel) to treat the serious complication, which the Tigenix and Takeda say affects around 28% of patients with Crohn's disease in ...
Takeda has chalked up another milestone for its Alofisel cell therapy for a complication of Crohn's disease, becoming the first allogeneic stem cell therapy to be approved in Japan.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback